

NOVO NORDISK A S  
Form 6-K  
July 06, 2010

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER**

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

**JULY 6, 2010**

---

**NOVO NORDISK A/S**

(Exact name of Registrant as specified in its charter)

**Novo Allé  
DK- 2880, Bagsvaerd  
Denmark**

(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-\_\_\_\_\_



## Company Announcement

5 July 2010

## Novo Nordisk A/S – Share repurchase programme

On 27 April 2010 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.5 billion in the period from 27 April 2010 to 3 August 2010.

Since the announcement as of 28 June 2010, the following transactions have been made under the programme:

	Number of shares	Average purchase price	Transaction value, DKK
<b>Accumulated, last announcement</b>	3,092,000		1,464,076,318
28 June 2010	65,000	504.0800	32,765,200
29 June 2010	75,000	495.9900	37,199,250
30 June 2010	100,000	494.3800	49,438,000
01 July 2010	165,000	487.4143	80,423,360
02 July 2010	80,000	484.1000	38,728,000
<b>Accumulated under the programme</b>	<b>3,577,000</b>		<b>1,702,630,127</b>

With the transactions stated above, Novo Nordisk owns a total of 18,321,872 treasury shares, corresponding to 3.1% of the share capital. The total amount of shares in the company is 600,000,000 including treasury shares.

Investor Relations 2880 Bagsværd +45 4444 8888 novonordisk.com 24256790

Denmark

Telefax:

+45 4444 6626

---

*Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 29,650 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](http://novonordisk.com).*

Further information:

Media:

Investors:

Mette Kruse Danielsen Klaus Bülow Davidsen

Tel: (+45) 4442 3883 Tel: (+45) 4442 3176

[mkd@novonordisk.com](mailto:mkd@novonordisk.com) [klda@novonordisk.com](mailto:klda@novonordisk.com)

Kasper Roseeuw Poulsen

Tel: (+45) 4442 4471

[krop@novonordisk.com](mailto:krop@novonordisk.com)

*In North America:*

*In North America:*

Sean Clements

Hans Rommer

Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937

[secl@novonordisk.com](mailto:secl@novonordisk.com) [hrrm@novonordisk.com](mailto:hrrm@novonordisk.com)

Company Announcement no 37 / 2010

Page 2 of 2

**Novo Nordisk A/S** Novo Allé

Telephone:

Internet:

CVR no:

Investor Relations 2880 Bagsværd

+45 4444 8888

[novonordisk.com](http://novonordisk.com)

24256790

Denmark

Telefax:

+45 4444 6626

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: JULY 6, 2010

NOVO NORDISK A/S

Lars Rebien Sørensen,

President and Chief Executive Officer

---